Neutrophil elastase (NE) is also released by TANs and can be endocytosed by tumor cells via neuropilin-1 (NRP1); this results in the cross-presentation of PR1, which is an NE-derived HLA-A2-restricted peptide that may be an immunotherapeutic target (109). This evidence concerns the gene NRP1 and neoplasm.